Lenvatinib 10 mg is a formulation of lenvatinib, an oral multi-kinase inhibitor used in the treatment of various cancers. Manufactured to meet rigorous pharmaceutical standards, lenvatinib delivers precision-targeted therapy aimed at inhibiting tumor growth and angiogenesis (formation of new blood vessels that feed tumors). It is prescribed primarily for specific types of thyroid cancer, liver cancer, kidney cancer, and endometrial cancer. Lenvatinib belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), and lenvatinib 10 mg offers a manageable dosage strength suitable for dose titration or maintenance therapy.

Composition and Strength

Each tablet of lenvatinib comprises:

Active component: Lenvatinib mesylate, which is equivalent to 10 mg of lenvatinib.

Darreichungsform: Tablette zum Einnehmen.

Packaging: Usually offered in the form of blister strips or bottles, based on the manufacturer’s design.

The 10 mg strength allows for dose adjustments as necessary. This is particularly useful for patients who need to have their dose adjusted because of tolerability issues or other health conditions.

Mechanism of Action

Lenvatinib is a multi-targeted tyrosine kinase inhibitor that disrupts various signaling pathways associated with cancer progression and angiogenesis. It inhibits specifically:

Rezeptoren des vaskulären endothelialen Wachstumsfaktors (VEGFR 1–3),

Receptors for fibroblast growth factor (FGFR 1–4),

alpha receptor for platelet-derived growth factor (PDGFRα),

Signaling pathways of RET and KIT.

lenvatinib hinders tumor growth and blood vessel development by obstructing these pathways, which prevents tumor cells from getting the signals they need—resulting in a slowdown or reduction of tumor advancement.

Indications and Uses

lenvatinib approved for treating the following types of cancer:

Differentiated Thyroid Cancer (DTC): For individuals with progressive DTC that does not respond to radioactive iodine.

Hepatocellular Carcinoma (HCC): Used as a primary treatment for those with liver cancer that cannot be surgically removed.

Renal Cell Carcinoma (RCC): Used alongside everolimus for patients who have not succeeded with prior anti-angiogenic treatment.

Endometrial Carcinoma: Alongside pembrolizumab for advanced endometrial carcinoma that is neither microsatellite instability-high (MSI-H) nor mismatch repair deficient (dMMR), and has progressed after previous systemic treatment.

Dosage and Administration

General Dosing: The dosage of lenvatinib 10 mg is determined by the type of cancer being treated and can be used on its own or in conjunction with other treatments.

Administration: To be taken by mouth once a day, irrespective of meals.

Adjustments: It may be necessary to modify the dose depending on side effects, liver or kidney function, or other medications being taken concurrently.

To achieve the best therapeutic effect and reduce side effects, patients should adhere closely to the guidance of their healthcare provider.

Side Effects and Precautions

As with all anticancer medications, lenvatinib 10 mg can lead to side effects. Typical side effects are:

High blood pressure (hypertension)

Müdigkeit

Durchfall

Reduced appetite

Reduction of weight

Vomiting and nausea

Hand-foot syndrome, also known as palmar-plantar erythrodysesthesia

Pain in joints or muscles

Less frequent but more severe side effects include:

Heart dysfunction

Hepatotoxizität

Kidney impairment

Eiweißausscheidung im Urin

Verlängerung des QT-Intervalls

Thromboembolic occurrences

Preventive measures:

Keep track of blood pressure regularly.

Carry out tests for liver and kidney functions.

During the treatment and for some time after it ends, rely on effective contraceptive measures.

Not advisable for pregnant or breastfeeding women.

Drug Interactions

Lenvatinib might have interactions with specific medications, including:

inhibitors/inducers of CYP3A4 (able to change lenvatinib levels)

Antihypertensive drugs

Other directed therapies or immune therapies

Patients need to notify their healthcare provider of all medications, supplements, or herbal products they are taking.

Storage and Handling

Store it at a room temperature of 20–25°C (or 68–77°F).

Shield from moisture and direct light.

Ensure that children cannot reach it.

After the date specified on the packaging, do not use.

Conclusion

lenvatinib provides a powerful and targeted strategy for controlling specific advanced or metastatic cancers. It plays an essential part in oncology treatment protocols, thanks to its clearly characterized mechanism of action and demonstrated clinical benefits. However, because of possible side effects and interactions, treatment should only be started and monitored by healthcare professionals with experience. It is essential to inform patients taking lenvatinib about the significance of sticking to their treatment, undergoing routine check-ups, and notifying their healthcare provider immediately about any abnormal signs.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of lenvatinib 10 mg?
lenvatinib is utilized for treating different types of cancer, such as thyroid cancer, hepatocellular carcinoma (liver cancer), and advanced renal cell carcinoma (kidney cancer), frequently alongside other therapies.

2. What is the mechanism of action of lenvatinib?
Lenvatinib acts as a tyrosine kinase inhibitor (TKI). It inhibits certain proteins (VEGFR, FGFR, PDGFR, RET, and KIT) that contribute to tumor growth and blood supply, aiding in the slowdown or cessation of cancer progression.

3. What is the proper way to take lenvatinib 10 mg?
It is administered orally once a day, regardless of meals. Swallow the capsule whole with water at the same time each day.

4. Is it safe to take lenvatinib alongside other cancer medications?
It is occasionally used in combination with other treatments, such as pembrolizumab (Keytruda) for advanced kidney cancer. Nonetheless, the combinations are contingent on the particular type of cancer and the patient’s condition.

5. Is it safe for women who are pregnant or breastfeeding to use lenvatinib?
Lenvatinib can be detrimental to an unborn child, making it inadvisable for use during pregnancy or lactation. During treatment and for at least one month afterward, effective contraception should be employed.